Introduction
Vernal keratoconjunctivitis (VKC) is a chronic, recurrent ocular allergic disease that primarily affects children and adolescents.
I 
Results
Data from 30 VKC patients and 10 controls were included in the statistical analysis. The median baseline tear L TB. and LTC. levels meas ured in VKC patients and the control group are summarised in Table 1 The median tear LTC. levels after treatment are presented in Table 2 , and these levels were again significantly lower than the baseline LTC. levels in all three treatment groups (p = 0.0209 for the lodoxamide group; p = 0.0284 for the DCC group; p = 0.0109 for the fIuorometholone group). The median tear LTC. level changes are presented in Fig. 2 . In all three treatment groups the median L TB. and LTC. levels after treatment were compared with those in the control group (Table 3 ). In the lodoxamide and DCC groups the median L TB. levels after treatment were lower than in the control group. In the fluorometholone group the L TB. levels after treatment were higher than in the control group but the difference was not statistically significant (p = 0.073). LTC. levels after treatment, although significantly lower than the baseline LTC. To compare the effectiveness of the three drugs, the median percentage reduction values presented in Table 2 were analysed using the Kruskal-Wallis test. There was no significant difference among the three treatment 
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294 Table 3 . Post-treatment median tear leukotriene B4 (LTB4) and leukotriene C4 (LTC4) levels of vernal keratoconjunctivitis patients in the three treatment groups compared with the controls LTB4 (pg/ml) LTC4 (pg/ml) 
Results are expressed as median (range).
DCG, disodium cromoglycate. "Statistical significance was p < 0.05.
Discussion
This Although all three drugs reduced tear L TC4 levels, these levels after treatment were still higher than in the control group. This finding can be explained by the presence of separate mechanisms in activation and inhibition of production and secretion of different classes of leukotrienes. These mechanisms are currently unclear.
The median clinical scores for signs and symptoms improved during the trial period while the tear L TB4 and LTC4 levels decreased in all treatment groups. This improvement in parallel with the decrease in tear leukotriene levels is another indication for the role of these substances in pathophysiology of VKC.
As L TC4 levels failed to decrease to control levels, we can conclude that over the period of treatment these three drugs could not completely block the pathological process. This may be one of the reasons why, in many clinical studies, treatments fail to resolve the signs and symptoms of VKC completely, although they reduce the signs and symptoms to some extent.,·22,2'
In our study fluorometholone was selected because of its lower potential for increasing intraocular pressure,
Comparing the effectiveness of these drugs, there were no significant differences between them regarding the reduction in L TB4 and L TC4 levels, and although lodoxamide and fluorometholone reduced the signs and symptoms scores a few days earlier than DCC there were no differences after the 20th day of treatment. We can therefore conclude that mast cell stabilisers are as effective as steroids, and are without the side-effects of the latter.
In conclusion, high levels of L TB4 and L TC4 in the tears of VKC patients may indicate the importance of lipoxygenase pathway products in the pathophysiology of allergic eye disorders, but more studies are required to reveal the complete pathophysiological mechanisms.
Better understanding of the role of lipoxygenase pathway products may also help to find a better treatment for VKC, through newer drugs with specific lipoxygenase inhibitory activity or antagonistic activities against lipoxygenase pathway products. Until such time, however, mast cell stabilisers must remain the first choice in the treatment of VKC.
